As 2019 draws to a close, the American Association for Cancer Research (AACR) is grateful for our growing ranks of cancer patients and survivors who join us in advocating for strong federal funding for medical research. This year, Tomma Hargraves and Nicole Robinson joined us on Capitol Hill for the Rally for Medical Research, an annual gathering in which more than 300 national organizations ask lawmakers to make continued funding for the National Institutes of Health a priority.Read More
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products (OHOP), which is responsible for reviewing cancer therapies, has been reorganized into the Office of Oncologic Diseases (OOD) as part of a broader effort within the Center for Drug Evaluation and Research to modernize its New Drugs Regulatory Program.Read More
Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the approval of safe and effective anticancer therapies. With the increasing complexity of cancer-related policy issues, the need for active engagement of cancer researchers and physician-scientists in the policymaking process has never been greater.Read More
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to efficiently answer important clinical, research, and regulatory questions around oncology treatments and outcomes. RWD can come from a variety of sources, including medical claims data, electronic health records, patient-reported outcomes, and product or disease registry data. Real-world evidence (RWE) is clinical evidence generated from these data.
While the randomized controlled trial remains the gold standard for gathering clinical evidence for regulatory use, RWE can provide critical insights in situations where such trials may be difficult to complete. This is especially relevant in oncology, where personalized medicine approaches are leading to increasingly smaller patient populations that necessitate new strategies for efficient drug development.Read More
In the past year, the number of American teenagers using tobacco products has increased by nearly 40 percent, reversing a trend that public health officials worked tirelessly to achieve.
The primary culprit in the resurgence of smoking? E-cigarettes. Taking aim at this growing public health problem, the American Association for Cancer Research (AACR) held a congressional briefing on Wednesday, June 12, titled “E-cigarettes and Nicotine Addiction: A Potential Health Crisis for Youth and Young Adults.” The roster of speakers included leaders from government, research, and policy sectors.
The tobacco product landscape is evolving and the AACR Tobacco Products and Cancer Subcommittee has been cognizant of the shift from combusted products (e.g., cigarettes) to alternative nicotine delivery systems, such as e-cigarettes. While it is generally accepted that e-cigarettes are safer than traditional cigarettes, these products still present risks and the AACR has been active in trying to keep children from having access to them.Read More
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or high response rates, they are not risk-free. Reports of immune-related adverse events (therapy-dependent toxicities caused by non-specific activation of the immune system) surfaced early in development for ipilimumab and accompany all approved immunotherapies.
The American Association for Cancer Research (AACR) will join the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases, and National Institute of Arthritis and Musculoskeletal and Skin Diseases to convene the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on April 15-16, 2019, in the Masur Auditorium on the National Institutes of Health campus in Bethesda, Maryland.Read More
Each year, the American Association for Cancer Research (AACR) holds Early-career Hill Day, bringing a group of AACR Associate members to Washington, D.C., to advocate for strong funding for cancer research and biomedical science. Along with representatives of the AACR’s Science Policy and Government Affairs office, they meet with lawmakers or members of their staffs, urging them to vote for continued robust funding for the National Institutes of Health (NIH) and National Cancer Institute.Read More
One late summer morning, I recall seeing a petite woman carrying two suitcases near the entrance to a hospital. She was alone and seemed indifferent to the commotion enveloping her.
This instance was mere moments long, yet it is ingrained in my memory. Because nearly six years ago, when I entered our cancer hospital on my first day as a doctoral student in cancer biology, this was exactly what I saw. I saw a woman, carrying her most precious belongings as she checked into the hospital for cancer treatment.
As I offered to help with her luggage, she kindly obliged and asked to share with me her story. Why? She wanted “at least one person to remember” her. And she got her wish, before succumbing to her disease two weeks later.Read More
On September 6, 2018, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research hosted a public workshop, Non-clinical Models for Safety Assessment of Immuno-Oncology Products. Academics, industry, regulators, and biomedical research funders gathered to review the state of the science and discuss opportunities to develop better non-clinical approaches for safety assessment and dose selection for immuno-oncology products in patients, with specific focus on immune checkpoint stimulators and inhibitors (ICS/ICI).Read More